Susceptibility of Bacterial Isolates From Turkey - A Report From the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program

• DOI: 10.1179/joc.2007.19.6.650
• Publication Date: 2014-01-09T18:06:08Z
• Authors: H. Eraksoy; A. Basustaoglu; V. Korten; H. Kurt; R. Ozturk; S. Ulusoy; A. Yaman; A. Yuce; P. Zarakolu
• Keywords: Acinetobacter baumannii; Ertapenem; Tazobactam; Klebsiella oxytoca

AbstractAbstractThe study monitored the susceptibility of nosocomial pathogens to meropenem and comparator antimicrobial agents isolated as part Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program from Turkish university hospitals. In terms minimum inhibitory concentration 90% (MIC90) values, was two- eight-fold more active than imipenem against Escherichia coli Klebsiella pneumoniae, respectively. 40.5% K. 23.1% oxytoca 15.3% E. isolates were extended-spectrum β-lactamase (ESBL) producers. Piperacillin/tazobactam most agent Pseudomonas aeruginosa, followed by imipenem. Against Acinetobacter baumannii isolates, agents. Continued surveillance MYSTIC appears be prudent help focus on effective empiric treatment regimens.Keywords: Antimicrobial resistancenosocomial infectionssusceptibility